<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04783727</url>
  </required_header>
  <id_info>
    <org_study_id>PredictEndTBSignature</org_study_id>
    <nct_id>NCT04783727</nct_id>
  </id_info>
  <brief_title>PredictEndTB Signature for Individualizing Treatment in Multidrug-Resistant Tuberculosis</brief_title>
  <official_title>Personalized Therapy Durations Defined by the Blood RNA-based Model for Individualizing Treatment in Multidrug-Resistant Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Research Center Borstel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Research Center Borstel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PredictEndTB signature is a non-inferiority, prospective, parallel-group open-label&#xD;
      randomized controlled trial evaluating the efficacy of individualised antituberculous&#xD;
      treatment durations that utilize the transcriptomic signature-based model compared to the&#xD;
      standardised twenty months treatment in a cohort of multidrug-resistant tuberculosis&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a non-inferiority, prospective, parallel-group open-label randomized controlled&#xD;
      trial. Three hundred forty-two HIV-negative patients diagnosed with pulmonary tuberculosis&#xD;
      (TB) and starting a new anti-multidrug-resistant tuberculosis (MDR-TB) treatment cycle will&#xD;
      be included in the study. Two randomized arms of 171 patients each will be recruited over the&#xD;
      two-year period, each patient will be followed-up over the entire course of anti-TB treatment&#xD;
      and one year after the end of therapy. Regular study visits will include physical&#xD;
      examination, collection of sputum, blood and urine and filling in the study questionnaire. On&#xD;
      the collected specimens standard bacteriological and blood tests, as well as extended&#xD;
      immunological analysis, will be performed. In the experimental group, an RNA transcriptomic&#xD;
      analysis using RNA-Seq technology will also be performed.&#xD;
&#xD;
      In the control arm, the patients will receive a standardised World Health Organization&#xD;
      recommended 20 months treatment while in the experimental arm the treatment duration will be&#xD;
      guided by the transcriptomic signature-based model.&#xD;
&#xD;
      Treatment outcomes and level of TB relapse and survival within the follow-up period will be&#xD;
      compared between the experimental and control arms. The efficacy of biomarker-guided&#xD;
      treatment therapy will be assessed by a comparison of the proportions of favourable study&#xD;
      outcome between two arms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">November 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>During the treatment, both Participant and Care Provider will be masked but once the treatment end is achieved, they will be unmasked, and study participation is continued.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with favourable study outcome 12 months after treatment end</measure>
    <time_frame>up to 36 months</time_frame>
    <description>The non-inferiority of the experimental arm compared to the control arm will be established if in the Per-Protocol population the difference in proportions of patients with a favourable study outcome between study arms is greater than the lower equivalence margin of 12%. This outcome measure is assessed after up to 24 months of treatment (usually 20 months) plus 12 months of follow-up after the end of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who was lost to follow-up during treatment</measure>
    <time_frame>up to 24 months</time_frame>
    <description>This outcome measure will be used in the secondary efficacy analysis in the Intention-to-Treat population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who had a treatment failure</measure>
    <time_frame>up to 24 months</time_frame>
    <description>This outcome measure will be used in the secondary efficacy analysis in the Intention-to-Treat population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who died from TB</measure>
    <time_frame>up to 36 months</time_frame>
    <description>This outcome measure will be used in the secondary efficacy analysis in the Intention-to-Treat population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who died of any cause</measure>
    <time_frame>up to 36 months</time_frame>
    <description>This outcome measure will be used in the secondary efficacy analysis in the Intention-to-Treat population</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of patients experiencing adverse events</measure>
    <time_frame>up to 24 months</time_frame>
    <description>This outcome measure will be used in the exploratory safety analysis in the safety population</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients who experienced TB relapse that was identified on early stages</measure>
    <time_frame>up to 36 months</time_frame>
    <description>This outcome measure will be used in the safety analysis in the safety population</description>
  </other_outcome>
  <other_outcome>
    <measure>Characteristics of the transcriptomic signatures obtained at the end of therapy time point and at follow-up visits</measure>
    <time_frame>up to 36 months</time_frame>
    <description>This outcome measure will be used in the exploratory safety analysis in the safety population</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">342</enrollment>
  <condition>Tuberculosis, Pulmonary</condition>
  <condition>Tuberculosis, Multidrug-Resistant</condition>
  <condition>Bacterial Infections</condition>
  <condition>Mycobacterial Infection</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The individualised treatment durations defined by the RNA transcriptomic signature-based model</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The locally accepted standard duration of treatment based on the WHO recommendation for treatment of MDR-TB patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Individualised treatment duration based on RNA transcriptomic model</intervention_name>
    <description>Anti-MDR-TB treatment with standard drugs and individual treatment duration guided by the RNA transcriptomic model; may be shorter or longer than standard WHO-recommended treatment duration of 20 months.</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient starting an MDR-TB treatment or within the first 4 weeks after treatment&#xD;
             initiation and before culture conversion.&#xD;
&#xD;
          -  Rifampicin resistant M. tuberculosis detected in sputum using a nucleic acid&#xD;
             amplification test.&#xD;
&#xD;
          -  New case of TB or re-treatment.&#xD;
&#xD;
          -  Can give informed consent at the point of recruitment.&#xD;
&#xD;
          -  Contactable (residing in the area covered by participating TB centres and possessing a&#xD;
             landline or a mobile phone).&#xD;
&#xD;
          -  Willing to participate for the entire course of the treatment and extensive follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years old.&#xD;
&#xD;
          -  Anti-MDR-TB therapy within 6 months prior to the start date of the current treatment&#xD;
             cycle.&#xD;
&#xD;
          -  HIV infection.&#xD;
&#xD;
          -  Non-adherent patient with frequent interruptions.&#xD;
&#xD;
          -  Patient in custodianship or guardianship.&#xD;
&#xD;
          -  Late exclusion criterion: no positive cultures at inclusion and within the first 3&#xD;
             months of treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Heyckendorf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Center Borstel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan Heyckendorf, MD</last_name>
    <phone>+49 4537 1882901</phone>
    <email>jheyckendorf@fz-borstel.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Irina Kontsevaya, PhD</last_name>
    <phone>+49 4537 1883677</phone>
    <email>ikontsevaya@fz-borstel.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Center Borstel</name>
      <address>
        <city>Borstel</city>
        <state>Schleswig-Holstein</state>
        <zip>23845</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Heyckendorf, MD</last_name>
      <phone>+49 4537 1882901</phone>
      <email>jheyckendorf@fz-borstel.de</email>
    </contact>
    <investigator>
      <last_name>Jan Heyckendorf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Lange, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irina Kontsevaya, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Phthisiopneumology Institute Chiril Draganiuc</name>
      <address>
        <city>Chisinau</city>
        <zip>2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sofia Alexandru, MD</last_name>
      <phone>+373 2257 2200</phone>
      <email>sofi.alexandru@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marius Nasta Pulmonology Institute</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elmira Ibraim, MD</last_name>
      <phone>+40 213 356 9101527</phone>
      <email>ielmira2000@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Roxana Mindru, MD</last_name>
      <phone>+40 213 356 9101484</phone>
      <email>roxanamindru@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Elmira Ibraim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kharkiv National Medical University</name>
      <address>
        <city>Kharkiv</city>
        <zip>61000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dmytro Butov, MD</last_name>
      <phone>+380 57707 7380</phone>
      <email>dddimad@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Pirogov Memorial Medical University</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrii Dudnik, MD</last_name>
      <phone>+380 432 570360</phone>
      <email>andriidudnyk@vnmu.edu.ua</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Moldova, Republic of</country>
    <country>Romania</country>
    <country>Ukraine</country>
  </location_countries>
  <reference>
    <citation>Heyckendorf J, Marwitz S, Reimann M, Avsar K, DiNardo AR, Günther G, Hoelscher M, Ibraim E, Kalsdorf B, Kaufmann SHE, Kontsevaya I, van Leth F, Mandalakas AM, Maurer FP, Müller M, Nitschkowski D, Olaru ID, Popa C, Rachow A, Rolling T, Rybniker J, Salzer HJF, Sanchez-Carballo P, Schuhmann M, Schaub D, Spinu V, Suárez I, Terhalle E, Unnewehr M, Weiner J 3rd, Goldmann T, Lange C. Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model. Eur Respir J. 2021 Sep 2;58(3). pii: 2003492. doi: 10.1183/13993003.03492-2020. Print 2021 Sep.</citation>
    <PMID>33574078</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tuberculosis</keyword>
  <keyword>multidrug resistance</keyword>
  <keyword>treatment duration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
    <mesh_term>Mycobacterium Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All study data will be pseudonymised and shared with other researchers only in pseudonymised form</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

